XSNX HUGE COMPANY ADDITION//Cleantech Innovator Dr. John

New Post Public Reply Private Reply Replies (0) Message Board

May 15, 2013 at 9:06 AM

[b]XSNX >>HUGE COMPANY ADDITION//Cleantech Innovator Dr. John Tuttle Joins XsunX Team[/b]

2013-05-15 09:00 ET - News Release

ALISO VIEJO, CA -- (Marketwired) -- 05/15/13

XsunX, Inc. (OTCQB: XSNX), the developer of CIGSolar®, a patent-pending technology for the mass production of CIGS solar cells that offers a capital-efficient, low-cost alternative to the use of silicon solar cells, today announced that the Dr. John R. Tuttle had joined the Company's Advisory Board. "John's extensive entrepreneurial background and comprehensive knowledge of the Cleantech industry is the perfect addition to XsunX at just the right time," stated XsunX CEO, Tom Djokovich.

Over the last several years, the Company has been developing its CIGSolar® technology while navigating the solar industry-wide restructuring. Recently XsunX began its transition from focusing on its CIGSolar baseline system design and build-out to marketing of its CIGSolar® technology. The next logical step was the addition of a seasoned industry innovation and business development veteran to aid in this transition and further development of XsunX's business relationships with customers and investors.

"There's been a paradigm shift occurring at virtually every level of the solar industry including, and most significantly, how business, the capital markets, and project finance assess the value of the solar industry as a whole and, more specifically, the value of any particular technology," added XsunX CEO Tom Djokovich. "Our current requirement was to find someone with world-class CIGS experience and someone who could also 'think outside of the box' -- or in the CIGS business -- outside of the vacuum chamber to commercialize technology. Dr. Tuttle's years of noteworthy experience at NREL elevating the science and capabilities of CIGS, and his experience transitioning innovation into operational results provides XsunX with the hands-on capabilities that we were looking for," concluded Mr. Djokovich.

Dr. Tuttle brings 30 years of experience in the semiconductor & photovoltaic industries to XsunX, and for the last several years has focused on assisting with operational and capital management of early-stage companies in the Cleantech sector. Previously, he was the co-founder, Chief Executive & Chairman of DayStar Technologies, Inc. where he took the company from 3 employees to an operational organization with world-class development and pilot production facilities, achieving an over 900% value creation for its IPO shareholders.

From 1986-1997, Dr. Tuttle held the position of Senior Scientist at NREL where his research guided the fabrication of thin-film CIGS PV devices with multiple world-record efficiencies. He has authored/co-authored over 70 publications, 14 Patent's / Patent applications, and conducted over 100 presentations about technology & business development. Dr. Tuttle holds a Ph.D. in EE from the University of Colorado, an M.S. from the Colorado School of Mines and a B.S in Applied and Engineering Physics from Cornell University. Dr. Tuttle is joining as Senior Scientific and Business Advisor to XsunX.

About XsunX

XsunX, Inc. is working to commercialize a new manufacturing process to produce low cost, high efficiency thin-film Copper Indium Gallium (di) Selenide (CIGS) thin film solar cells. Our patent-pending processing technology, which we call CIGSolar®, focuses on the mass production of thin-film CIGS solar cells utilizing a proprietary multi-area thermal deposition process to minimize processing defects to create highly uniform CIGS films. These cells match silicon solar cell dimensions and can be offered as a non-toxic, high-efficiency and lowest-cost alternative to the use of silicon solar cells. The company is offering licenses for the use of the CIGSolar® process technology, and plans to generate revenue through licensing fees and manufacturing royalties for the use of the CIGSolar® technology.

For more information please call XsunX at 888-797-4527, or visit the company's website at www.xsunx.com.

Safe Harbor Statement

Matters discussed in this press release contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the Company's actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as "may," "will," "should," "believes," "expect," "intend," "anticipate," "plan," "estimate" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject to risks and uncertainties that are described in our most recent annual report on Form 10-K under the heading "Risk Factors" and our subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements whether as a result of the receipt of new information, future events, or otherwise.

XsunX
888-797-4527
www.xsunx.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...